Evidence map›Paper›PMID 39833157›Full record

ArticleNature communications2025

Dynamic allostery in the peptide/MHC complex enables TCR neoantigen selectivity.

Jiaqi Ma, Cory M Ayres, Chad A Brambley, Smita S Chandran, Tatiana J Rosales, W W J Gihan Perera, Bassant Eldaly, William T Murray, Steven A Corcelli, Evgenii L Kovrigin and 2 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. HLA micropolymorphisms confine neoantigen conformational adaptability and guide T cell receptor selectivity.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Solution mapping of MHC-I:TCR interactions using a minimalistic protein system.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  10. Review
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Jiaqi Ma *Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, USA.ORCID http://orcid.org/0000-0002-6298-0193
Cory M Ayres *Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, USA.ORCID http://orcid.org/0000-0001-9846-8020
Chad A BrambleyDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, USA.ORCID http://orcid.org/0000-0001-9429-2048
Smita S ChandranHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA.
Tatiana J RosalesDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, USA.
W W J Gihan PereraDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, USA.
Bassant EldalyDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, USA.ORCID http://orcid.org/0009-0009-9532-8546
William T MurrayHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA.
Steven A CorcelliDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, USA.
Evgenii L KovriginDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, USA.
Christopher A KlebanoffHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA.ORCID http://orcid.org/0000-0001-9645-3896
Brian M BakerDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, USA. brian-baker@nd.edu.ORCID http://orcid.org/0000-0002-0864-0964

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
User Training & OutreachP30GM138396 · NIGMS · UCHICAGO ARGONNE, LLC · PI JANET L. SMITH · 2020 to 2026
$34.3M
User Training and OutreachP30GM124165 · NIGMS · CORNELL UNIVERSITY · PI Nozomi Ando, J Christopher Fromme · 2018 to 2026
$34.2M
TR&D 3: TECHNOLOGY DEVELOPMENT FOR NMR STUDIES OF SMALL MOLECULES (METABOLOMICS, NATURAL PRODUCTS, METABOLITE-PROTEIN INTERACTIONS) pp.537-585 P41GM103399 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI MARKLEY, JOHN LUTE · 2012 to 2019
$9.4M
Technologies for Solid-State NMR Data CollectionP41GM136463 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI WESTLER, WILLIAM MILO · 2021 to 2025
$6.4M
NMR User Program at NMRFAMR24GM141526 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Katherine Anne Henzler-Wildman · 2021 to 2026
$6.4M
Structural biophysics and molecular design in cellular immunityR35GM118166 · NIGMS · UNIVERSITY OF NOTRE DAME · PI BAKER, BRIAN M · 2016 to 2025
$4.4M
Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene.R37CA259177 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Christopher Austin Klebanoff · 2021 to 2026
$3.1M
TOX-driven CD8 T cell differentiation and dysfunction in tumorsR01CA269733 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Andrea Schietinger · 2023 to 2026
$2.4M
Novel cell therapy approaches for molecularly defined subsets of therapy-resistant melanomaR01CA286507 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Christopher Austin Klebanoff · 2023 to 2026
$1.8M
Integrated state-of-the-art LC-MS/NMR system for the University of WisconsinS10RR025062 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI MARKLEY, JOHN LUTE · 2008 to 2008
$1.7M
Upgrade of the NMRFAM 750 MHz NMR SpectrometerS10RR029220 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI MARKLEY, JOHN LUTE · 2010 to 2010
$766k
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA269733NCI NIH HHS R01 CA286507NCI NIH HHS R37 CA259177NCRR NIH HHS S10 RR023438NCRR NIH HHS S10 RR025062NCRR NIH HHS S10 RR029220NIGMS NIH HHS P30 GM124165NIGMS NIH HHS P30 GM138396NIGMS NIH HHS P41 GM103399NIGMS NIH HHS P41 GM136463NIGMS NIH HHS R24 GM141526NIGMS NIH HHS R35 GM118166NIH HHS S10 OD028553U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R37CA259177U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R35GM118116
6 · The paper itself

Abstract

The inherent antigen cross-reactivity of the T cell receptor (TCR) is balanced by high specificity. Surprisingly, TCR specificity often manifests in ways not easily interpreted from static structures. Here we show that TCR discrimination between an HLA-A*03:01 (HLA-A3)-restricted public neoantigen and its wild-type (WT) counterpart emerges from distinct motions within the HLA-A3 peptide binding groove that vary with the identity of the peptide's first primary anchor. These motions create a dynamic gate that, in the presence of the WT peptide, impedes a large conformational change required for TCR binding. The neoantigen is insusceptible to this limiting dynamic, and, with the gate open, upon TCR binding the central tryptophan can transit underneath the peptide backbone to the opposing side of the HLA-A3 peptide binding groove. Our findings thus reveal a novel mechanism driving TCR specificity for a cancer neoantigen that is rooted in the dynamic and allosteric nature of peptide/MHC-I binding grooves, with implications for resolving long-standing and often confounding questions about T cell specificity.

Indexed as

Antigens, NeoplasmPeptidesReceptors, Antigen, T-CellAllosteric RegulationCross ReactionsHumansProtein BindingAntigens, NeoplasmPeptidesReceptors, Antigen, T-Cell

Identifiers

PMID39833157
PMCPMC11756396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.